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The incidence of end-stage renal disease (ESRD) owing to
diabetes has continued to increase despite the extensive use
of angiotensin-converting enzyme (ACE) inhibitors to prevent
diabetic nephropathy, primarily from evidence of short-term
effectiveness. We assessed the long-term effect of ACE
inhibitors on the risk of ESRD. We formed a population-based
cohort of all diabetic patients treated with antihypertensive
drugs in the Province of Saskatchewan, Canada, between
1982 and 1986. The patients were followed up to the end of
1997 to identify cases of end-stage renal failure. A nested
case–control analysis was used with the controls matched to
each case on age, diabetes type, and duration of follow-up.
The cohort comprised 6102 subjects, of which the 102 cases
who developed end-stage renal failure were matched to 4129
controls. Relative to thiazide diuretic use, the adjusted rate
ratio of end-stage renal failure associated with the use of ACE
inhibitors was 2.5 (95% confidence interval 1.3–4.7), whereas
it was 0.8 (95% confidence interval 0.5–1.4) for beta-blockers
and 0.7 (95% confidence interval 0.4–1.3) for calcium
antagonists. The rate ratio of end-stage renal failure with the
use of ACE inhibitors was 0.8 (95% confidence interval
0.3–2.5) during the first 3 years of follow-up, but increased
to 4.2 (95% confidence interval 2.0–9.0) after 3 years.
ACE-inhibitor use does not appear to decrease the long-term
risk of end-stage renal failure in diabetes. Our data suggest
instead that ACE inhibitors might actually increase this risk,
which may possibly contribute to the continued increasing
incidence of ESRD owing to diabetes.
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Angiotensin-converting enzyme (ACE) inhibitors have been
used for an increasing number of indications since their
introduction as antihypertensive drug therapy for treatment-
resistant hypertension.1–6 One of these suggested indications,
namely slowing the rate of progression of nephropathy in
diabetic patients with or without hypertension,3 can
potentially have a major impact on this disease. Indeed,
diabetic nephropathy, occurring in 20–40% of diabetics, is
currently believed to be the most important cause of
morbidity and mortality among diabetic patients.7 As
diabetic nephropathy accounts for nearly 45% of new
patients reaching end-stage renal disease (ESRD) in the
USA, the clinical impact of potential ACE-inhibitor-mediated
renal effects, beyond that resulting from blood pressure
reduction, should be substantial.8 However, despite the
extensive use of ACE inhibitors to prevent diabetic nephro-
pathy, the incidence of ESRD owing to diabetes in the USA
has increased 266% in the decade between 1984 and 1994.9
Although increasing incidence of diabetes, longer survival,
and liberalized acceptance criteria of ESRD programs may
account for a part of it, other possible explanations should be
entertained.10
The evidence for the effectiveness of ACE inhibitors in
preventing diabetic nephropathy is surprisingly not persua-
sive. Although numerous studies have been conducted on the
renal effects of ACE inhibitors, including a meta-analysis of
more than a hundred studies that suggested that ACE
inhibitors were unique in decreasing proteinuria, beyond that
mediated by their hypotensive effect, and had a favorable
effect on decline in glomerular filtration rate,11 studies based
on major outcomes are not all as decisive. In type I diabetes,
the ACE inhibitor captopril was shown to reduce the 3-year
rate of progression to dialysis, renal transplantation, or death,
as well as doubling of serum creatinine, in patients with
existing diabetic nephropathy and serum creatinines exceed-
ing 1.5 mg/dl at study entry.12 On the other hand, in a trial of
hypertensive patients with type II diabetes with no nephro-
pathy, the United Kingdom Prospective Diabetes study
showed that patients on captopril had similar rates of renal
failure to patients on atenolol, a beta-blocker, after more than
8 years follow-up.13 The MIcroalbuminuria, Cardiovascular,
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2006 International Society of Nephrology
Received 21 April 2005; revised 12 September 2005; accepted 6 October
2005; published online 18 January 2006
Correspondence: S Suissa, The Departments of Epidemiology and
Biostatistics and of Medicine, Division of Clinical Epidemiology, Royal
Victoria Hospital, McGill University Health Centre, 687 Pine avenue west, Ross
4.29, Montreal, Que´bec, Canada H3A 1A1. E-mail: samy.suissa@clinepi.mcgill.ca
Kidney International (2006) 69, 913–919 913
and Renal Outcomes (MICRO)-Heart Outcomes Prevention
Evaluation study found no reduction in the rate of dialysis, a
secondary outcome, in patients predominantly with type II
diabetes given the ACE inhibitor ramipril after 4.5 years of
follow-up.14 Two recent randomized trials assessing the
effectiveness of angiotensin-receptor blockers in patients
with type II diabetes and pre-existing kidney disease found
slightly lower rates of ESRD relative to placebo over 4
years.15,16 The Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial study, which includes
36% of patients with type II diabetes showed no difference in
the rate of decline of glomerular filtration rate or rate of
development of ESRD between the ACE inhibitor lisinopril
and the diuretic chlorthalidone after 6 years of follow-up. No
separate analysis for diabetic patients is given.17 Thus, no
study has yet evaluated the long-term renal effects of ACE
inhibitors in type I diabetic patients and the only study that
did so in type II diabetics (United Kingdom Prospective
Diabetes Study), a trial of tight blood pressure control that
does not represent the typical clinical experience, found no
benefit.
In this population-based cohort study, we assess the long-
term effect of ACE-inhibitor use on the incidence of end-
stage renal failure in a large cohort of hypertensive diabetic
patients.
RESULTS
The cohort consisted of 6102 diabetic patients who were
dispensed an antihypertensive drug between 1982 and 1986,
after excluding 37 subjects who had been hospitalized for
renal disease before cohort entry. At cohort entry, the mean
age was 66 years, 55% were male and 40% were first-time
users of antihypertensive drugs. At cohort entry, the mean
duration of diabetes was around 6 years and 44% of the
cohort subjects entered the cohort treated exclusively with
oral hypoglycemic agents.
During cohort follow-up, that averaged 7.8 years, 133
subjects required some dialysis treatment, of which 102
satisfied our criteria for end-stage renal failure. The
corresponding rate of ESRD was 2.13 per 1000 per year
and the time from cohort entry to the onset of renal failure
was 5 years, ranging from 3 days to 13.5 years. Entry into the
cohort was gradual over time with 16.7% entering the cohort
in 1982 up to 26.5% in 1986. Half of the cases occurred
during 1987–1991, whereas around a quarter of them
occurred during each of 1982–1986 and 1992–1997.
All 4129 cohort members who could be matched to the
cases were identified. Characteristics of the cases and their
matched controls, both around 57 years of age, are presented
in Table 1. The cases included more males and most used
insulin. The median duration of diabetes was over 16 years.
Thus, the mean time from the start of treated diabetes to
outcome requiring dialysis was over 21 years for the cases.
Although they were rather comparable with respect to cardio-
vascular disease before cohort entry, cases were much more
likely to have had developed heart failure during follow-up.
Table 2 displays the rate ratio of renal failure for the
various classes of antihypertensive drugs dispensed during
the first 90 days of follow-up. The adjusted rate ratio of ACE-
inhibitor use, relative to thiazide diuretic use, is 2.5 (95%
confidence interval 1.3–4.7). On the other hand, beta-
blockers and calcium antagonists are not associated with
renal failure risk.
Table 3 presents the rate ratio of renal failure for ACE-
inhibitor use as a function of the duration of follow-up.
During the first 3 years of follow-up, the adjusted rate ratio is
0.8 (95% confidence interval 0.3–2.5). However, the rate ratio
after 3 years of follow-up is 4.2 (95% confidence interval
2.0–9.0). Among subjects with over 3 years of follow-up,
Table 4 shows that the continuance of ACE-inhibitor use
during both the first 3 years of follow-up and thereafter is
associated with a rate ratio of renal failure of 7.5 (95%
confidence interval 2.8–20.1), whereas for the use of ACE
inhibitors only during the first 3 years, the rate ratio was 2.3
(95% confidence interval 0.3–17.5). On the other hand, ACE-
inhibitor use initiated after 3 years of hypertension is
associated with a rate ratio of 4.9 (95% confidence interval
2.4–9.8).
Table 5 indicates that the rate ratio of renal failure
associated with ACE-inhibitor use is consistent across
patients with or without heart failure before the index date,
as well as patients who entered the cohort before or after
December 31, 1985. It appears, however, that patients with
type II diabetes (treated with oral hypoglycemics with or
without insulin) have a higher rate ratio for ACE-inhibitor
use than patients with type I diabetes (treated exclusively
with insulin), although the two rate ratios are not
significantly different (P¼ 0.08).
Table 1 | Characteristics of cases and controls
Cases Controls
Number 102 4129
Age at index datea (years; mean7s.d.) 56.6715.7 57.272.4
Sex (% male) 61.8 51.4
Time from cohort entry to index datea (years;
mean7s.d.)
4.973.4 4.970.5
Diabetes treatment before index datea (%)
Insulin only 45.1 45.1
Oral hypoglycemics only 13.7 13.7
Insulin and oral hypoglycemics 41.2 41.2




Before cohort entry 11.8 15.4
Between cohort entry and index date 30.4 24.8
Congestive heart failure before index date (%)
Before cohort entry 12.8 9.0
Between cohort entry and index date 36.3 14.4
Hypertensive drug use before cohort entry (%) 51.0 48.4
aMatching factors.
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Table 2 | Crude and adjusted rate ratio of renal failure for ACE inhibitors and other antihypertensive drugs used during the first
90 days of follow-up
Adjustedc
Antihypertensive drug dispensed during






rate ratio Rate ratio 95% CI
Thiazide diuretics 45.1 51.0 1.0 1.0 Reference
ACE inhibitors: 20.6 7.8 2.9 2.5 1.3–4.7
Beta-blockers 18.6 27.8 0.8 0.8 0.5–1.4
Calcium antagonists 11.8 16.8 0.8 0.7 0.4–1.3
ACE=angiotensin-converting enzyme; CI=confidence interval.
aMore than one agent, including other antihypertensive drugs and loop-diuretics, could have been dispensed.
bMatched on age, type of diabetes treatment (insulin only, oral hypoglycemics only, or combined therapy), and duration of treated diabetes.
cAdjusted, in addition to the matching factors, for one another, sex, continuous age, year of cohort entry, concurrent use of other antihypertensive drugs and loop-diuretics,
and cardiovascular disease and congestive heart failure, both before cohort entry and during follow-up.
Table 3 | Crude and adjusted rate ratio of renal failure for ACE inhibitor use during the first 90 days of follow-up as a function
of follow-up time
Cases Controls Adjusteda
Duration of follow-up (years) Number Percent users Number Percent users Crude rate ratio Rate ratio 95% CI
o3 36 16.7 1511 11.0 1.1 0.8 0.3–2.5
3–6 31 32.3 1182 9.0 5.0 4.5 1.6–12.9
46 35 14.3 1436 3.6 3.8 3.6 1.1–11.9
ACE=angiotensin-converting enzyme; CI=confidence interval.
aAdjusted, in addition to the matching factors, for concurrent use of other antihypertensive drugs and loop-diuretics, sex, continuous age, year of cohort entry, and
cardiovascular disease and congestive heart failure, both before cohort entry and during follow-up.
Table 4 | Crude and adjusted rate ratio of renal failure for continuance of ACE inhibitor drug use during follow-up among
subjects with over 3 years of follow-up
Adjusteda
Cases Controls Crude rate ratio Rate ratio 95% CI
Number of subjects 66 2618
ACE inhibitor use during follow-up among subjects with over 3 years of follow-up
First 3 years and after 3 years 19.7 4.1 8.0 7.5 2.8–20.1
First 3 years but not thereafter 3.0 2.0 2.6 2.3 0.3–17.5
Started use after 3 years only 48.5 21.1 5.1 4.9 2.4–9.8
ACE=angiotensin-converting enzyme; CI=confidence interval.
aAdjusted, in addition to the matching factors, for concurrent use of other antihypertensive drugs and loop-diuretics, sex, continuous age, year of cohort entry, and
cardiovascular disease and congestive heart failure, both before cohort entry and during follow-up.
Table 5 | Adjusted rate ratio of renal failure for ACE inhibitor use during the first 90 days of follow-up as a function of heart
failure, year of cohort entry, and treatment of diabetes
Cases Controls Adjusteda
Stratum Number Percent users Number Percent users Rate ratio 95% CI
Heart failure before cohort entry
No 61 21.3 3144 7.7 2.7 1.3–8.2
Yes 41 19.5 985 8.6 2.2 0.5–4.7
Year of cohort entry
1982–1985 75 10.7 3154 3.9 2.1 1.0–9.6
1986 27 48.2 975 18.9 2.8 0.7–4.9
Diabetes type (treatment) before index date
Type I (insulin only) 46 19.6 892 10.3 1.4 0.5–3.7
Type II (oral hypoglycemics with or without insulin) 56 21.4 3237 5.8 4.1 1.8–9.2
ACE=angiotensin-converting enzyme; CI=confidence interval.
aAdjusted, in addition to the matching factors, for concurrent use of other antihypertensive drugs and loop-diuretics, sex, continuous age, year of cohort entry, and
cardiovascular disease and congestive heart failure, both before cohort entry and during follow-up. For each stratified model, however, the stratification variable is not used
as an adjustment factor.
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DISCUSSION
We found that the use of ACE inhibitors by patients with
diabetes is not associated with a long-term decreased risk of
renal failure. Our findings suggest instead a higher risk of
renal failure in those who took ACE inhibitors, even when we
controlled for other risk factors.
Our findings may appear at first glance to contradict
several studies on this question. The large meta-analysis,11
which summarized the evidence from more than a hundred
studies on the issue, showed that ACE inhibitors decreased
proteinuria beyond that mediated by their hypotensive effect,
and had a favorable effect on glomerular filtration rate.
However, this effect was not seen in a sub-analysis restricted
to the 11 randomized, controlled trials included in the meta-
analysis. Several other trials showed that ACE inhibitors
clearly reduce albuminuria in both type I and type II diabetes
mellitus, irrespective of blood pressure level, with consistent
antiproteinuric effects.12,18–29 Although evidence from these
studies has been interpreted as clearly demonstrating the
beneficial renal effects of ACE inhibitors, there have been
dissenting opinions30–37 and calls for definitive long-term
clinical trials to provide proof for the postulated effects.38
One of the central issues in interpreting these and other
studies on this issue revolves around the choice of outcome.
Although it is generally recognized that outcomes employed
in definitive studies need to be of direct clinical relevance,39
such as mortality and morbidity, only five such studies have
been conducted to date. The only study that did show a
benefit for ACE inhibitors on renal disease in type I diabetes
patients was based on patients with already evident diabetic
nephropathy whose serum creatinine exceeded 1.5 mg/dl at
study entry and only 3 years of follow-up.12 In type II
diabetes, on the other hand, the United Kingdom Prospective
Diabetes study showed that patients who were given an ACE
inhibitor had similar rates of renal failure than patients on a
beta-blocker (rate ratio 0.91), after more than 8 years follow-
up.13 This study, however, had very low power to detect
pragmatic differences, with only eight cases of renal failure in
both groups combined. Moreover, the recent MICRO-Heart
Outcomes Prevention Evaluation study found no reduction
in the rate of progression to dialysis (rate ratio 1.22) in
patients primarily with type II diabetes given an ACE
inhibitor, albeit only after 2.5 years of follow-up.14 The two
most recent randomized trials of angiotensin-II-receptor
blockers in type II diabetes patients with pre-existing kidney
disease found slightly lower rates of ESRD relative to placebo
over 4 years (rate ratios 0.83 and 0.72).15,16 Thus, our finding
of ACE inhibitors being associated with no decrease in the
risk of renal failure compared with other antihypertensive
agents over the long term in this largely type II diabetic
cohort is consistent with these studies that either found no
effect in the long term or a small beneficial effect during the
first 3 to 4 years, but did not follow-up thereafter.
The finding of an elevated risk may have at least two
possible explanations. First, it could be that ACE inhibitors
prolong life, thus increasing the opportunity for ESRD
incidence. Alternatively, ACE inhibitors, while apparently
providing an early benefit to the kidney, could in fact damage
the kidney in the longer term by mechanisms still unknown.
Such a possibility needs to be studied in longer-term animal
and possibly human studies. If such a mechanism exists, it is
one of many potential explanations for the exponential rise in
ESRD owing to diabetes over the past two decades.10
Our study design has strengths and limitations. Although
a randomized trial would have been the preferred design, it
would be expensive, lengthy, given the need to recruit large
numbers and the extended follow-up, and may in fact not
even be feasible. Indeed, we can anticipate that there may be
difficulties in recruiting large numbers of patients with
diabetes in such a trial, as their treating physicians may be
reluctant to deprive them of the antiatherosclerotic effect of
ACE inhibitors for over 10 years. Thus, our cohort study was
designed specifically to emulate a randomized trial and to
avoid confounding by indication, which arises from non-
comparability of groups owing to selective prescribing and
tends to bias the results of non-experimental studies of
intended effects.40 This was achieved by selecting the period
of cohort entry to be between 1982 and 1986, as ACE
inhibitors were first introduced in Saskatchewan in 1982 and
clinical recommendations regarding the beneficial renal
effects of ACE inhibitors came only after 1986. Indeed,
animal experiments suggesting that ACE inhibitors were
superior to other antihypertensive drugs in retarding the
progression of renal disease were first reported in 1986,41 and
it was only several years later that ACE inhibitors were
recommended for clinical use in diabetic patients.42 Thus,
direct confounding by indication for renal disease was likely
absent from the cohort.
On the other hand, indirect confounding could have been
present from the indication of ACE inhibitors for patients
with congestive heart failure. The first trial showing the
benefit of ACE inhibitors in congestive heart failure was
published in 1987,43 and some physicians may have already
been using them between 1982 and 1986, which could have
biased our study. This factor is an important potential
confounding factor as it was also associated with an increased
risk of end-stage renal failure in our study (rate ratio 2.9). We
therefore controlled for this diagnosis in our analyses, both
pre-existing before cohort entry or if it developed during
follow-up. In stratifying for this diagnosis, we found that the
rate ratio associated with ACE-inhibitor use was similar in
patients with and without heart failure. The results, that still
show an increased risk of end-stage renal failure in users of
ACE inhibitors, decrease the likelihood, but do not eliminate
the possibility of residual confounding by indication.
Another aspect of confounding by indication is that calcium
antagonists, which were also introduced in Saskatchewan in
the early 1980s and could have thus been subject to similar
selective prescribing, did not show an elevated rate ratio.
Finally, the outcome we used, namely end-stage renal failure
requiring dialysis treatment, has a low chance of misclassi-
fication and thus could not have biased the results in any
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important way. Moreover, the fact that the rate ratios were
consistent across subgroups of patients, such as the type of
diabetes, the duration of hypertension, and the use of ACE
inhibitors alone or in combination, substantiates the findings
of this study.
This study indicates that the use of ACE inhibitors by
patients with diabetes does not appear to decrease the long-
term risk of ESRD. These data, in fact, suggest that this risk
may be increased with ACE inhibitors. Whether clinicians
should reconsider using these drugs in patients with diabetes
to prevent kidney disease is unclear. Indeed, these drugs have
been shown to be highly effective, compared with placebo, at
preventing cardiovascular outcomes in this population. On
the other hand, long-term studies have shown that they are
just as effective as beta-blockers and that the focus of
treatment should be on tight blood pressure control. More
long-term studies of these major outcomes are needed to
justify the extensive use of these drugs for renal protection in
patients with diabetes.
MATERIALS AND METHODS
We used a population-based historical cohort study design,
specifically devised to emulate a randomized, controlled trial.
Sources of data
The computerized databases of Saskatchewan Health, developed as a
result of the universal health insurance program provided to
residents of this Canadian province since 1975, formed the primary
source of data for this study. All Saskatchewan residents (over 1
million) with a valid Health Services Card are eligible for coverage,
with the exception of registered Indians and members of the Armed
Forces, who in total represent less than 5% of the population. The
databases contain identification and demographic details of all
residents eligible for health services in Saskatchewan, as well as the
date of death or the date of termination of coverage if the subject
moved out of the Province. The prescription drugs’ database
contains data on outpatient prescription drug use, including the
identity of the drug, its strength, and dosage form, as well as the date
and quantity dispensed. The hospital data file contains data on all
hospitalizations in Saskatchewan and includes information on
primary and secondary discharge diagnoses, date of discharge,
length of stay, and vital status at separation. The physician services
database contains information on diagnosis and services rendered.
These databases have been used extensively to study the effects of
several prescription drugs at the population level.44,45
Cohort definition
All dispensed prescriptions for insulin and oral hypoglycemic agents
were first used to identify the source population of diabetic subjects
in Saskatchewan treated between the years 1976 and 1986. From this
population, we formed the cohort of all subjects who were
dispensed, during the period 1982 to 1986, the following
antihypertensive medications: ACE inhibitors, beta-blockers, cal-
cium channel blockers, thiazide diuretics, loop diuretics, and other
agents, primarily consisting of methyldopa and hydralazine. The
period for cohort entry was selected to start in 1982 as this is the
year that ACE inhibitors were introduced in Saskatchewan. Cohort
entry continued until December 31, 1986, so that subjects who
received their first antihypertensive prescription after this date could
not be enrolled as members of the cohort. This specific cohort
closing date of December 1986 was chosen to ensure that
confounding by indication does not bias the assessment of
effectiveness, as the potential beneficial renal effects of ACE
inhibitors only started to be discovered at that time41 and clinical
recommendations about this specific use only came much later.42
For subjects who initiated antihypertensive therapy between 1982
and 1986, time zero into the cohort was taken to be the date the first
antihypertensive drug was dispensed. For subjects who initiated
antihypertensive therapy before 1982, the definition of time zero
depended on the antihypertensive agent. If those subjects had
switched from any agent, primarily diuretics or beta-blockers, to
either an ACE inhibitor or a calcium channel blocker between 1982
and 1986, the date of dispensing of the latter two was taken to be
time zero. In subjects who used solely other agents between 1982
and 1986, time zero was taken to be a randomly selected dispensing
date during this accrual period. Subjects were excluded if they had
been hospitalized during the 2 years before cohort entry for acute
renal failure, end-stage renal failure, renal transplantation, nephritis,
nephropathy, nephrotic syndrome, unspecified renal failure, dis-
orders resulting from impaired renal function and small kidney of
unknown cause, or had received a treatment of dialysis.
All subjects were followed up until the date of coverage
termination, of death, of the renal outcome under study, or
December 1997, whichever occurred first. All prescriptions for
antihypertensive drugs, other cardiovascular drugs, antidiabetic
drugs dispensed throughout the follow-up, as well as all hospitaliza-
tions occurring during this period, were obtained.
Outcome
The outcome under study was end-stage renal failure requiring
dialysis. Outcome data were obtained through the hospitalization
and physician services databases. Chronic dialysis treatment was
identified from a combination of the service dates for all dialysis
treatments rendered and hospitalizations for end-stage renal failure
requiring dialysis (ICD-9 code V56). The outcome was defined as
requiring dialysis treatment of at least 6 weeks duration. Subjects
with a duration of less than 6 weeks of dialysis, but who died within
this treatment period, were also considered as cases if there were no
indication that their renal failure was acute. The timing of the
outcome was taken to be the first course of chronic dialysis.
Analysis
The study was designed to emulate a clinical trial with treatment
allocation occurring at cohort entry. The primary analysis was thus
an intention-to-treat analysis, based on the antihypertensive drugs
dispensed at cohort entry. Owing to the large size of the cohort and
the time-dependent nature of some covariates, a nested case–control
approach to analysis was employed as an equivalent alternative to
the proportional hazards model with time-dependent factors.46 For
each case of renal failure identified during follow-up, the risk set for
this analysis was formed with all cohort members with a duration of
follow-up as long or longer than the case’s. The case’s date of dialysis
initiation was taken to be the index date for the case and the
members of each risk set. Within each of these risk sets, we selected
all controls who could be matched to the case on the type of diabetes
treatment (insulin only, oral hypoglycemics only, combined therapy)
before the index date, the duration of diabetes at the index date, as
well as age within 5 years. The calculation of diabetes duration was
incomplete for some subjects as data on treatment were only
available as of 1976. Thus, the duration of diabetes was censored for
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subjects who already had diabetes in 1976. Accordingly, the product-
limit method was used to estimate the median duration of diabetes.
The rate ratio of renal failure associated with ACE-inhibitor use
was estimated using conditional logistic regression, accounting for
the matched nature of the risk sets. The primary measure of
exposure at cohort entry was taken from the antihypertensive drugs
dispensed during the first 90 days of follow-up after cohort entry. As
subjects could have received more than one type of antihypertensive
drug during this period, the regression analysis provided the
independent effect of each antihypertensive drug type on the risk.
The choice of 90 days was intended to be sufficiently short to avoid
confounding by indication and long enough to capture other
antihypertensive drugs given around the time of cohort entry, but
not on that exact day. To compare the short- and long-term effects
of ACE inhibitors, we repeated the analysis after stratification by
more or less than 3 years of follow-up, the typical period employed
in short-term trials.12,14
In addition to the matching factors, namely age within 5 years,
type, and duration of diabetes, several potential confounding factors
were used to adjust the estimated rate ratios. Besides sex, continuous
age was used to account for residual confounding from the 10-year
matching age categories. The year of cohort entry, from 1982 to
1986, was used to control for secular trends in antihypertensive drug
use, whereas the use of antihypertensive drugs before cohort entry
was used to control for prior hypertension. Cardiovascular disease
and congestive heart failure, before cohort entry as well as during
follow-up, were also used as covariates. Cardiovascular disease
included hospitalizations for myocardial infarction, angina, and
other acute and chronic ischemic heart disease, as well as
prescriptions of nitrates. Congestive heart failure was defined by a
hospitalization or by the dispensing of digoxin. The study had 80%
power to detect the a priori hypothesized 40% reduction in the rate
of the renal failure secondary to ACE-inhibitor use.
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